Press Room

Biotheranostics appoints F. Anthony Greco, M.D. as Medical Advisor for its CancerTYPE ID® molecular assay
Biotheranostics, Inc. announces F. Anthony Greco, MD as Medical Advisor for its CancerTYPE ID® test. CancerTYPE ID helps with identification of tumor type and subtype when a diagnosis remains unclear following standard diagnostic evaluation...
Breast Cancer Index® and New Data on its Power to Predict Extended Endocrine Therapy Benefit Presented at ASCO 2019
Biotheranostics, Inc. announces new pivotal data on the Breast Cancer Index® (BCI) being presented at the ASCO conference June 3rd, 2019 that further validates its ability to accurately predict...
Breast Cancer Index® Now Covered by Medicare for a Broader Group of Post-Menopausal Patients Considering Extended Endocrine Therapy
Biotheranostics, Inc., announces expanded Medicare coverage for its Breast Cancer Index® test under a new Local Coverage Determination [(LCD) L37822], effective today...
Breast Cancer Index® Receives Expanded Medicare Coverage Under a New Local Coverage Determination
Biotheranostics, Inc., announces its Breast Cancer Index (BCI) test has been issued a new Medicare Local Coverage Determination [(LCD) L37822] by Noridian, effective April 16, 2019...
Biotheranostics Presents New Data on the Breast Cancer Index® at the San Antonio Breast Cancer Symposium
Biotheranostics, Inc., announced the presentation of new data at the 2018 San Antonio Breast Cancer Symposium evaluating the impact of the Breast Cancer Index (BCI) in early stage hormone receptor positive (HR+) breast cancer patients classified as intermediate risk for distant recurrence by previous genomic testing...
Biotheranostics' Breast Cancer Index® Recently Recognized in Two National Clinical Practice Guidelines
Biotheranostics, Inc. announces recommendations for Breast Cancer Index in both the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and the American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer...
Biotheranostics Announces Presentation of Key Data for CancerTYPE ID® and Breast Cancer IndexTM at ASCO Annual Meeting in Chicago
Biotheranostics, Inc. announces new data from studies for both of its proprietary molecular diagnostic tests, CancerTYPE ID (CTID) and Breast Cancer Index (BCI) to be presented on Saturday, June 2nd and Monday, June 4th at the annual meeting of the American Society of Clinical Oncology...
CancerTYPE® ID Prospective Trial Published in ASCO Journal of Precision Oncology
Biotheranostics, Inc., reports publication in JCO Precision Oncology of a prospective, multi-institutional, clinical utility study evaluating the impact of CancerTYPE ID on final diagnosis and treatment in patients...
Biotheranostics Announces Its Breast Cancer Index Gene-Only Test Provides The Most Significant Prognostic Information For Breast Cancer Recurrence
Biotheranostics, Inc. announces publication of comparative performance results of its Breast Cancer Index (BCI) with other commercially available genomic tests for women with early stage hormone receptor positive breast cancer...
Newly Published Data Expands Clinical Utility of Breast Cancer IndexSM to Include Early-Stage, ER+ Patients with Node Positive Disease
Biotheranostics today announced publication in the Clinical Cancer Research journal of a study evaluating performance of a Breast Cancer Index (BCI) that was specifically developed ...
Breast Cancer IndexSM Identifies a subset of Clinically Low Risk Patients Who May Require Longer Therapy
A recent publication in npj Breast Cancer reports that Breast Cancer Index (BCI), a genomic test performed by Biotheranostics, Inc., identifies patients...
New Data Affirms Value of Breast Cancer Index (BCI) in Identification of Early Stage ER+ Breast Cancer Patients Appropriate for Extended Endocrine Therapy (EET)
Biotheranostics, Inc. today announced new data further demonstrating the importance of BCI in clinical practice. In a study of more than 14,000 cases...
Biotheranostics Appoints Don Hardison as New CEO
Biotheranostics, Inc., a growing molecular diagnostics company, today announced the appointment of Don Hardison as Chief Executive Officer...
Biotheranostics Presents First Data from the BCI Clinical Database for Correlative Studies
A recent analysis from the newly developed Breast Cancer Index (BCI) Clinical Database for Correlative Studies was presented at the 18th American Society of Breast Surgeons Annual Meeting in Las Vegas, NV...
Breast Cancer Index SM (BCI) Included in Updated Guidelines for Use of Clinical Biomarkers in Breast Cancer
New guidelines recently published by the European Group on Tumor Markers (EGTM) recommend that the validated biomarker, Breast Cancer IndexSM (BCI), may be...
Study Demonstrates Use of Breast Cancer IndexSM (BCI) Leads to Significant Changes in Physician Recommendations for Extended Endocrine Therapy in ER+ Breast Cancer Patients
Results from a new multi-institutional study assessing the role of Breast Cancer IndexSM (BCI) in treatment decision-making for ER+ breast cancer patients who are considering...
Study Presented at San Antonio Breast Cancer Symposium Demonstrates Strong Performance of Biotheranostics' 92-gene Assay in the Diagnosis of Triple Negative Breast Cancer
A study showing the strong performance of an optimized version of...
Breast Cancer IndexSM Predicted Patients at High Risk of Recurrence Despite Low Risk Clinical Features, New Data Suggest
Results from new analyses of two cohorts demonstrate that Breast Cancer Index (BCI), a genomic biomarker performed by Biotheranostics, Inc....
New Data Substantiate the Ability of Breast Cancer IndexSM to Help Physicians Identify Early Stage ER+ Breast Cancer Patients for Extended Anti-Estrogen Therapy
Biotheranostics today announced that new data will be presented demonstrating the role of the Breast Cancer Index (BCI) in identifying which patients with early stage, ER+ breast cancer are...
Biotheranostics & Syapse Collaborate to Integrate Genomics-Based Molecular Diagnostics for Cancer into the Syapse Precision Medicine Platform
Biotheranostics, Inc., a pioneer in molecular diagnostics for cancer, and Syapse, the leader in precision medicine software...
Biotheranostics Appoints Industry Veteran Don Hardison to Board of Directors
Biotheranostics, Inc., today announced that Don Hardison has been appointed to its Board of Directors...
Biotheranostics' Announces New Data Presented at 2016 ASCO Annual Meeting
Biotheranostics announced new independent data validating a new Breast Cancer Index (BCI)...
Study Presented at ASCO 2016 Shows Clinical Utility of Biotheranostics' CancerTYPE ID® in Predicting Tumor Type & Aiding in Treatment Optimization for Metastatic Cancer Patients
A study demonstrating the clinical utility of Biotheranostics' CancerTYPE® ID molecular cancer classifier...
Clinical Cancer Research Publishes Study Demonstrating Clinically Meaningful and Statistically Significant Prognostic Improvement by the Breast Cancer IndexSM...
Clinical Cancer Research, the official journal of the American Association for Cancer Research, reported results of an...
Biotheranostics' Chief Scientific Officer Nominated for Athena Pinnacle Award
Catherine Schnabel, Ph.D., recognized for supporting women in the San Diego Life Sciences Industry ...
Biotheranostics Raises $32 Million in a Private Equity Financing & Announces Spinout From bioMérieux
bioTheranostics, a leader in molecular diagnostics for cancer, today announced that ...
Studies Demonstrate Broadening Clinical Utility of Biotheranostics' Breast Cancer Index Molecular Test in the Extended Endocrine Setting
Results Presented at San Antonio Breast Cancer Symposium Illustrate BCI's Contribution to Advancing Clinical Care
Yale Study Shows bioTheranostics' Breast Cancer Index MolecularSM Test Impacts Extended Endocrine Therapy Decisions in clinical practice
Clinical Use of Breast Cancer Index Led to Fewer Recommendations for Treatment & Reduced Patient Anxiety
Biotheranostics Announces Collaboration with DeNovo Sciences to Evaluate Its Proprietary Cancer Biomarkers for Use in Liquid Biopsies
bioTheranostics, Inc., a leader in molecular diagnostics for cancer, today announced a collaboration agreement with DeNovoSciences, Inc., ...
Journal of the National Comprehensive Cancer Network Review Article Highlights Role of Biotheranostics' Breast Cancer IndexSM in Optimizing Endocrine Therapy
Molecular test facilitates more personalized treatment, helping determine which patients with early stage, ER+ breast cancer are likely to benefit from extended endocrine therapy
ASCO Conference Data Show Biotheranostics' Molecular Tests Significantly Impact Management of Metastatic Cancer Patients
Two Key Studies Support Role of CancerTYPE ID® Molecular Cancer Classifier & CancerTREATMENT NGS+ Biomarker Panels in Diagnosis & Management of Challenging Cancers
Studies Presented at 2015 ASCO Meeting Demonstrate Predictive Power of Biotheranostics' Breast Cancer IndexSM Molecular Test in Endocrine Therapy Decisions
Ability to Predict Benefit from Extended Endocrine Therapy Impacts Treatment & Reduces Patient Anxiety
Study Underscores Value of Biotheranostics' Breast Cancer IndexSM in Informing Decisions about Long-Term Endocrine Therapy & Assessing Risk of Late Recurrence
Miami Breast Cancer Conference Study & Workshop Reinforce Clinical Utility of Test Along the Continuum of Patient Care
Lifetime's "The Balancing Act" Show for Women to Discuss the Breast Cancer IndexSM Molecular Test
Lifetime's "The Balancing Act" Show for Women to Discuss the Breast ...
Biotheranostics Appoints Key Executives to Leadership Team
FOR IMMEDIATE RELEASE...Jan. 9, 2015...SAN DIEGO...bioTheranostics, Inc., a leader in molecular ...
Studies Reinforce Unique Predictive and Prognostic Abilities of Biotheranostics' Breast Cancer Index Molecular Test
Results Presented at San Antonio Breast Cancer Symposium Demonstrate Strength of Breast Cancer Index
Biotheranostics' Breast Cancer IndexSM Genomic Test Selected as Finalist in 27th Annual CONNECT Most Innovative New Product Awards
SAN DIEGO, Calif....Nov. 10, 2014...bioTheranostics, Inc., a leading genomic solutions provider for cancer, today announced that its Breast Cancer IndexSM molecular test has been ...